Skip to main content
. 2023 Jan 20;47(4):251–256. doi: 10.1038/s41366-023-01254-z

Fig. 2. Non-fatal major cardiovascular events.

Fig. 2

Freedom of non-fatal major adverse cardiovascular events (MACE) up to 8 years after initiation of GLP-1 receptor agonists or metabolic and bariatric surgery in persons with type 2 diabetes.